SARS-CoV-2 RBD Expression in Mammalian Cells for High-Yield Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The lack of high-yield production of viral proteins for diagnostic tests and therapeutic interventions for COVID-19 limits the development of effective tools against SARS-CoV-2 infections.
Innovation Solution
Development of genetically modified mammalian cells that express recombinant SARS-CoV-2 receptor binding domain (RBD) polypeptides with high purity and proper folding, linked to peptide tags for efficient protein production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to produce viral proteins, then production complexity is reduced, but production yield and purity are insufficient
Solution Approach 1:
The viral protein production system is segmented into modular components: expression vectors with specific promoters, genetically modified mammalian cells with optimized transcriptional machinery, and purified protein extraction systems. This segmentation allows each component to be optimized independently while achieving high overall productivity and purity for SARS-CoV-2 RBD proteins.
Solution Approach 2:
Genetically modified mammalian cells serve as intermediary systems between the genetic blueprint (expression vectors) and the final product (purified viral proteins). These intermediary cells provide the necessary cellular machinery for proper protein folding, glycosylation, and high-yield production, bridging the gap between simple expression and complex protein functionality.
2Quantity of substance
If high-yield production systems are implemented, then protein availability improves, but production cost and complexity increase
Solution Approach 1:
The genetically modified mammalian cell system is designed to perform multiple functions simultaneously: high-level protein expression, proper post-translational modifications (glycosylation), correct protein folding, and scalable production. This multi-functionality reduces the need for separate production and purification steps, lowering overall manufacturing costs while maintaining high protein availability.
Solution Approach 2:
The system optimizes multiple parameters including promoter strength, transcription factor expression levels, cellular metabolism, and protein secretion efficiency. By changing these parameters in the mammalian cell system, the patent achieves high-yield production with improved cost-effectiveness compared to traditional systems requiring more complex purification protocols.
3Productivity
If recombinant protein expression is used, then production scalability improves, but protein folding and glycosylation quality may deteriorate
Solution Approach 1:
Mammalian cells act as intermediary systems that preserve native protein folding and glycosylation pathways while enabling scalable recombinant production. The cellular machinery of these intermediary organisms ensures proper disulfide bond formation, chaperone-mediated folding, and complex glycan attachment, maintaining manufacturing precision even at large production scales.
Solution Approach 2:
The genetically modified mammalian cells utilize their own endogenous protein folding and glycosylation machinery to process the recombinant SARS-CoV-2 RBD proteins. This self-service approach ensures proper protein structure and functionality without requiring external intervention or complex quality control steps, enabling both scalability and high manufacturing precision.
Data Source
AI summary
The present disclosure provides an isolated or purified SARS-CoV-2 Receptor Binding Domain (RBD) polypeptide and cells for producing such a polypeptide, as well as compositions and methods thereof.